

GREEN LIGHT COMMITTEE
THE STOP TB PARTNERSHIP WORKING GROUP



GREEN LIGHT COMMITTEE APPLICATION INSTRUCTIONS

Subgroup of the stop tb partnership working group on multidrug-resistant tuberculosis

Ref: WHO/HTM/TB/2010.1

© World Health Organization 2010

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed in Switzerland.

GREEN LIGHT COMMITTEE
THE STOP TB PARTNERSHIP WORKING GROUP
World Health Organization
20, Avenue Appia
1211 Geneva 27, Switzerland

Contents

CONTRIBUTORS	i
INTRODUCTION	2
OVERVIEW OF APPLICATION PROCESS	4
Phases of the application process.....	5
1. Pre-application Phase.....	5
2. Application Phase	5
3. Approval Phase	6
4. Operation Phase.....	6
Application Procedure for Programme/Project Expansion.....	7
1. Full expansion application	7
2. Expansion request based on the GLC monitoring mission report	7
Programmes/projects for small numbers of patients	8
INSTRUCTIONS FOR APPLICANTS	9
Cover Letter	9
Body of the Application	10
1. Background	11
2. Existing TB care and control programme/project.....	11
3. Information on DR-TB in the area and past and future use of SLD	12
4. Government Commitment and Partnerships.....	12
5. Organization, Management and Coordination	12
6. Case finding, diagnosis and definitions.....	13
7. Laboratory Aspects	13
8. Infection control aspects	14
9. Treatment and Follow-up Strategy	14
10. Side effects monitoring and management.....	15
11. Treatment delivery and adherence	15
12. Patient rights and responsibilities	15
13. Drug management.....	16
14. Information Systems and Data Management	16
15. Annexes of the application.....	16
ADDRESS AND SCHEDULE FOR SUBMITTING APPLICATIONS.....	18
REFERENCES	19
ANNEX A	20
ANNEX B	20
ANNEX C	21



Contributors

Contributors to the original and revised versions :

Kai Blöndal, Jose A. Caminero, Helene Castel, Peter Cegielski, Gunta Dravniece, Marcos A. Espinal, Ernesto Jaramillo, Fabienne Jouberton, Agnes Gebhard, Case Gordon, Myriam Henkens, Timothy Holtz, Salmaan Keshavjee, Jim Y. Kim, Kitty Lambregts-van Weezenbeek, Vaira Leimane, John Loeber, Robert H. Matiru, Paloma Marroquin Lerga, Juliet Melzer, Fuad Mirzayev, Joia Mukherjee, Eva Nathanson, Charles Nolan, Domingo Palmero, Martins Pavelsons, Mario C. Raviglione, Michael L. Rich, Maria Sarquella, Fabio Scano, Arnaud Trebucq, Karin Weyer.



Introduction

Management of drug-resistant tuberculosis (DR-TB) under programmatic conditions is a complex intervention in public health, not yet fully established in many countries. The treatment that does not meet international standards, however, risks amplifying and spreading multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) further. The global response to MDR-TB and XDR-TB, embedded in the Global Plan to Stop TB 2006-2015¹, has the target of achieving universal access to diagnosis and treatment of MDR-TB by 2015. The WHO *Guidelines For The Programmatic Management Of Drug Resistant Tuberculosis* (herein after referred to as the WHO Guidelines)² provide recommendations for appropriate management of DR-TB to control it, avoid generation of further drug resistance and taking into consideration community based / ambulatory and patient centered care. The Green Light Committee (GLC) was created by WHO and its partners in January 2000 with the objective to help programmes/projects³ develop and implement strategies for the management of DR-TB,

The GLC a subgroup of the Stop TB Partnership's Working Group on MDR-TB and serves both WHO and the Stop TB Partnership (STP) as an advisory body. The GLC has the following functions:

- Evaluates applications for access to second-line anti-TB drugs (SLD) in relation to current WHO guidelines, available evidence, and collective experience;
- Advises WHO and the STP as to the outcome of each application;
- Monitors the progress and performance of GLC-approved programmes/projects;
- Promotes the development of programme/project capacity to manage DR-TB;
- Promotes capacity development for expert technical assistance and consultation on DR-TB;
- Promotes and participates in the analysis of data from GLC-approved programs and in the dissemination of new data-driven information on treatment of DR-TB.

Today GLC forms part of the Green Light Committee Initiative ("GLC Initiative"), which is a mechanism that:

- Establishes compliance of country MDR-TB programmes/projects with the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis and other international standards set in the field of TB care and control;
- Enables access to affordable, high-quality, second-line anti-TB drugs for the treatment of MDR-TB;
- Provides monitoring and technical assistance to countries in scaling up their MDR-TB programmes/projects;

¹ <http://www.stoptb.org/globalplan/>

² WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, emergency update 2008 (WHO/HTM/TB/2008.402 http://www.who.int/tb/publications/2008/programmatic_guidelines_for_mdrtb/en/index.html.)

³ The GLC encourages countries to scale up their MDR-TB response by changing initial projects with small patient cohorts into nation-wide MDR-TB programmes.

- Advises WHO on policy-related matters to effectively prevent and control MDR-TB based on the best available scientific evidence;
- Fosters research to strengthen the evidence base for the programmatic management of DR-TB.

The GLC consists of nine member institutions⁴ that are drawn from the Stop TB Partnership Working Group on MDR-TB and chosen based on a competitive selection process which is regulated by the GLC Operating Procedures. The member institutions have a demonstrated leadership in public health and are active in TB care and control internationally. Each member institution is represented by two experts in programmatic, scientific, clinical, or microbiological aspects of TB who serve WHO in an advisory capacity. The GLC freely consults outside experts as needed. All members are required to adhere to rules of conflict of interest and confidentiality and, thus, cannot participate in the decision-making on applications from programmes/projects, in relation to which they have or had a direct or perceived conflict of interest. Each institution is allowed one vote, and all decisions are taken on the basis of consensus.

The services offered by the GLC include the following:

- Pre-application assistance with DR-TB programme/project development and needs assessment;
- Expert technical review of applications;
- Evaluation of proposed programmes/projects;
- Regular monitoring of approved programmes/projects;
- Peer support and knowledge sharing with other GLC-approved programmes/projects;
- Promotion of training and technical assistance;
- Contribution to the evidence base for the programmatic management of DR-TB.

The Global Drug Facility (GDF) is presently the procurement arm of the GLC Initiative, with the Secretariat housed at WHO, which, together with its procurement agent(s) coordinates and implements drug order processes. Currently, all GLC approved programmes/projects are required to use the GDF procurement mechanism. GDF can begin providing services after a programme/project has received approval from the GLC in the so called operation phase. For detailed instructions on procurement, please refer to the Procurement Manual for MDR-TB Projects under the Green Light Committee Mechanism⁵.

To benefit from the services of the GLC and, more broadly, of the GLC Initiative, programmes/projects must: (1) build on the foundation of a solid DOTS-based TB care and control programme/project; (2) design their programme/project within the principles put forth in the most recent WHO *Guidelines*; and (3) write their application in the format prescribed in these *Green Light Committee Application Instructions* (herein after referred to as the *Instructions*). Programmes/projects receiving approval can benefit from the pooled procurement of WHO prequalified quality assured SLD at preferential prices. Moreover, the application process leads to enhanced communication between programme/project sites, WHO, other public health agencies and the GLC Initiative. It also facilitates technical assistance to the programmes/projects. Feedback from programmes/projects provides important clinical and programmatic experience needed to develop global standards for the prevention and control of DR-TB.

The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund) at its Third Board Meeting⁶ recognized that the GLC provides a package of services for MDR-TB care and control that cannot be disaggregated. It further determined that Principal Recipients of Global Fund grants would be required to procure SLD through the GLC Initiative, including the pooled procurement mechanism (Third Board Decision).

⁴ The current GLC member institutions are Partners In Health (PIH), KNCV Tuberculosis Foundation, International Union Against Tuberculosis & Lung Disease (IUATLD), Infectious Diseases Hospital F. J. Muñiz (HFJM), U.S. Centers for Disease Control and Prevention (CDC), State Agency for TB & Lung Disease, Latvia, Médecins sans Frontières (MSF), World Health Organization (WHO), Indus Hospital.

⁵ http://whqlibdoc.who.int/hq/2008/WHO_HTM_STB_2008.51.pdf

⁶ GF/B4/2 (January 2003).

The Global Fund at its Thirteenth Board Meeting⁷ determined that Country Coordination Mechanisms (CCMs) applying for funding of MDR-TB care and control activities in a Proposal under Round 6 and subsequent rounds of funding, or in a Request for Continued Funding, must include in their Proposals or Requests for Continued Funding provision to share the cost of the GLC Initiative and reaffirmed the Third Board Decision. The Global Fund, in consultation with the GLC, has defined the cost-sharing element for GLC services as a flat rate per grant per year that will not exceed \$50,000 per grant per calendar year (ending 31 December) (the "Cost-Sharing Element"). Countries using the GLC mechanism and basing themselves on the Global Fund funding must include this flat-rate payment in their Global Fund grant application budgets.

These Instructions were designed and written to be used in conjunction with the following source material, available at no cost from WHO in paper or the world wide web:

World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, emergency update 2008 (WHO/HTM/TB/2008.402)

http://www.who.int/tb/publications/2008/programmatic_guidelines_for_mdrtb/en/index.html

World Health Organization. Treatment of TB Guidelines - 4th Edition (WHO/HTM/TB/2009.420);

http://www.who.int/tb/publications/2009/who_htm_tb_2009_420_beforeprint.pdf

World Health Organization. Procurement Manual for MDR-TB projects under the Green Light Committee mechanism, September 2008, (WHO/HTM/STB/2008.51);

http://whqlibdoc.who.int/hq/2008/WHO_HTM_STB_2008.51.pdf

WHO policy on TB infection control in health-care facilities, congregate settings and households;

http://whqlibdoc.who.int/publications/2009/9789241598323_eng.pdf

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29051

